Nicolas Gendron on Sustainability in Anticoagulation and DOACs
Nicolas Gendron, Research Fellow, Hematologist at Boston Children’s Hospital, shared on LinkedIn:
”Anticoagulation and sustainability. What is the carbon impact of DOACs?
Our study, published in Haematologica Journal, compares for the first time the carbon footprint of the three DOACs used in France (dabigatran, apixaban, rivaroxaban) using two life cycle analysis databases, Ecovamed and MCF.
The main findings:
- DOACs do not have the same carbon footprint, despite similar efficacy and safety.
- Dabigatran has a much higher carbon impact than anti-Xa drugs (apixaban and rivaroxaban), with a footprint that is 3 to 36 times higher depending on the indications and databases.
- Most of dabigatran’s impact comes from its active ingredient, which is very energy-intensive to produce.
- Conversely, for apixaban and rivaroxaban, nearly 70% of the carbon impact is linked to corporate activities (RandD, distribution, administration, etc.).
- Lower doses, used for prolonged treatments, significantly reduce emissions.
DOACs are among the most widely prescribed drugs in the world.
At a time when the healthcare system needs to reduce its environmental footprint, these results show that, given equivalent efficacy and safety, the choice of treatment can have a major environmental impact.
Our study advocates for integrating environmental criteria into treatment decisions whenever possible, without ever compromising the quality of care.
Proud of this collective work.
Well done Laurence Chery, Zahra Hassani, Lise Durand, Dorothee Boisseau, Victorien Monguillon, David Grimaldi, Sebastien Taillemite, and Benjamin de Sainte Marie.
Thank you to Ecovamed for providing access to their high-quality data.
Thank you to SESAME.
Let’s continue to move towards cutting-edge, low-carbon medicine.”
Read the full article here.
Article: Carbon footprint of direct oral anticoagulants in atrial fibrillation and venous thromboembolism
Authors: Laurence Chery, Zahra Hassani, Lise Durand, Dorothee Boisseau, Victorien Monguillon, David Grimaldi, Sebastien Taillemite, Benjamin de Sainte Marie, Nicolas Gendron
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 9, 2026, 09:29Veronica Sanchez: A Framework for Woman’s Health
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause